rosiglitazone has been researched along with AIDS Seroconversion in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bondy, G; Elliott, T; Frohlich, J; Harris, M; Montaner, J; Normén, L | 1 |
| Haider, DG; Ludvik, B; Luger, A; Mittermayer, F; Müller, M; Nowotny, P; Rieger, A; Schindler, K; Wolzt, M | 1 |
1 trial(s) available for rosiglitazone and AIDS Seroconversion
| Article | Year |
|---|---|
Effect of rosiglitazone on visfatin and retinol-binding protein-4 plasma concentrations in HIV-positive patients.
Topics: Adiponectin; Adipose Tissue; Adult; Cytokines; Female; HIV Seropositivity; Humans; Hypoglycemic Agents; Insulin Resistance; Leptin; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; Regression Analysis; Retinol-Binding Proteins; Retinol-Binding Proteins, Plasma; Rosiglitazone; Thiazolidinediones | 2007 |
1 other study(ies) available for rosiglitazone and AIDS Seroconversion
| Article | Year |
|---|---|
Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol.
Topics: Cholesterol, HDL; Diabetes Complications; Diabetes Mellitus; Female; Fenofibrate; HIV Seropositivity; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Lipids; Male; Middle Aged; Retrospective Studies; Rosiglitazone; Thiazolidinediones | 2004 |